104 related articles for article (PubMed ID: 12872295)
1. Chronic opioid antagonist treatment selectively regulates trafficking and signaling proteins in mouse spinal cord.
Patel CN; Rajashekara V; Patel K; Purohit V; Yoburn BC
Synapse; 2003 Oct; 50(1):67-76. PubMed ID: 12872295
[TBL] [Abstract][Full Text] [Related]
2. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
Zhang Q; Purohit V; Yoburn BC
Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
[TBL] [Abstract][Full Text] [Related]
3. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
4. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
Patel MB; Patel CN; Rajashekara V; Yoburn BC
Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
[TBL] [Abstract][Full Text] [Related]
5. Antagonist-induced micro-opioid receptor up-regulation decreases G-protein receptor kinase-2 and dynamin-2 abundance in mouse spinal cord.
Patel M; Gomes B; Patel C; Yoburn BC
Eur J Pharmacol; 2002 Jun; 446(1-3):37-42. PubMed ID: 12098583
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment with the opioid antagonist naltrexone favours the coupling of spinal cord μ-opioid receptors to Gαz protein subunits.
Valdizán EM; Díaz A; Pilar-Cuéllar F; Lantero A; Mostany R; Villar AV; Laorden ML; Hurlé MA
Neuropharmacology; 2012 Feb; 62(2):757-64. PubMed ID: 21903117
[TBL] [Abstract][Full Text] [Related]
7. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
8. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
Duttaroy A; Yoburn BC
Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
[TBL] [Abstract][Full Text] [Related]
9. The effect of nimodipine on opioid antagonist-induced upregulation and supersensitivity.
Lee SC; Yoburn BC
Pharmacol Biochem Behav; 2000 Jun; 66(2):347-51. PubMed ID: 10880689
[TBL] [Abstract][Full Text] [Related]
10. Chronic opioid antagonist treatment dose-dependently regulates mu-opioid receptors and trafficking proteins in vivo.
Rajashekara V; Patel CN; Patel K; Purohit V; Yoburn BC
Pharmacol Biochem Behav; 2003 Jul; 75(4):909-13. PubMed ID: 12957235
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
12. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
13. The effect of mu-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation.
Shah S; Duttaroy A; Chen BT; Carroll J; Yoburn BC
Brain Res Bull; 1997; 42(6):479-84. PubMed ID: 9128924
[TBL] [Abstract][Full Text] [Related]
14. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
[TBL] [Abstract][Full Text] [Related]
15. The role of opioid receptor density in morphine tolerance.
Lutfy K; Yoburn BC
J Pharmacol Exp Ther; 1991 Feb; 256(2):575-80. PubMed ID: 1847202
[TBL] [Abstract][Full Text] [Related]
16. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
[TBL] [Abstract][Full Text] [Related]
17. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
18. Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism.
Díaz A; Pazos A; Flórez J; Ayesta FJ; Santana V; Hurlé MA
Neuroscience; 2002; 112(2):345-53. PubMed ID: 12044452
[TBL] [Abstract][Full Text] [Related]
19. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
20. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
